Skip to main content
. 2020 Feb 13;12(2):432. doi: 10.3390/cancers12020432

Figure 2.

Figure 2

The effect of low molecular weight heparins (LMWHs) on heparan sulfate proteoglycans/heparanase. LMWHs antagonize the activity of heparanase through increased tissue factor pathway inhibitor (TFPI) release and the inhibition of vascular endothelial growth factor A (VEGF-A) and fibroblast growth factor 2 (FGF-2). They also inhibit the degradation of extracellular matrix (ECM), resulting in reducing desmoplasia in the TME.